| pubmed-article:10682666 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C0079419 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C0683956 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:10682666 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:10682666 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10682666 | pubmed:dateCreated | 2000-3-2 | lld:pubmed |
| pubmed-article:10682666 | pubmed:abstractText | The purpose of this work was to analyse the ability of p53 and thymidilate synthase (TS) primary tumour expression to retrospectively predict clinical response to chemotherapy and long-term prognosis in patients with advanced colorectal cancers homogeneously treated by methotrexate (MTX)-modulated-5-fluorouracil (5-FU-FA). A total of 108 advanced colorectal cancer patients entered the present retrospective study. Immunohistochemical p53 (pAb 1801 mAb) and TS (TS106 mAb) expression on formalin-fixed paraffin-embedded primary tumour specimens was related to probability of clinical response to chemotherapy, time to progression and overall survival. p53 was expressed in 53/108 (49%) tumours, while 54/108 (50%) showed TS immunostaining. No relationship was demonstrated between p53 positivity and clinical response to chemotherapy (objective response (OR): 20% vs 23%, in p53+ and p53- cases respectively) or overall survival. Percent of OR was significantly higher in TS-negative with respect to TS-positive tumours (30% vs 15% respectively; P < 0.04); simultaneous analysis of TS and p53 indicated 7% OR for p53-positive/TS-positive tumours vs 46% for p53-positive/TS-negative tumours (P < 0.03). Logistic regression analysis confirmed a significant association between TS tumour status and clinical response to chemotherapy (hazard ratio (HR): 2.91; 95% confidence interval (CI) 8.34-1.01; two-sided P < 0.05). A multivariate analysis of overall survival showed that only a small number of metastatic sites was statistically relevant (HR 1.89; 95% CI 2.85-1.26; two-sided P < 0.03). Our study suggests that immunohistochemical expression of p53 and TS could assist the clinician in predicting response of colorectal cancer patients to modulated MTX-5-FU therapy. | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10682666 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10682666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10682666 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10682666 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10682666 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:SimoneGG | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:RomeroAA | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:De LenaMM | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:JohnstonP GPG | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:ParadisoAA | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:PetroniSS | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:AllegraC JCJ | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:LeoneBB | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:MachiavelliMM | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:VallejoCC | lld:pubmed |
| pubmed-article:10682666 | pubmed:author | pubmed-author:LacavaJJ | lld:pubmed |
| pubmed-article:10682666 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10682666 | pubmed:volume | 82 | lld:pubmed |
| pubmed-article:10682666 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10682666 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10682666 | pubmed:pagination | 560-7 | lld:pubmed |
| pubmed-article:10682666 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:meshHeading | pubmed-meshheading:10682666... | lld:pubmed |
| pubmed-article:10682666 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10682666 | pubmed:articleTitle | Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. | lld:pubmed |
| pubmed-article:10682666 | pubmed:affiliation | Clinical Experimental Oncology Laboratory, Oncology Institute, Bari, Italy. anpara@tin.it | lld:pubmed |
| pubmed-article:10682666 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10682666 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10682666 | lld:pubmed |
